This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Egg phospholipids is a compound used as a calorie source in parenteral nutrition.
- Generic Name
- Egg phospholipids
- DrugBank Accession Number
- DB14233
- Background
Egg phospholipids are primarily a mixture of naturally occurring phospholipids which are isolated from the egg yolk. Egg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.
- Type
- Biotech
- Groups
- Approved, Experimental, Investigational
- Synonyms
- Egg lecithin
- Egg lecithin component of endolipide
- Egg oil lecithin
- Egg oil phospholipids
- Egg phosphatides
- Egg phospholipid
- Egg phospholipids
- Egg yolk lecithin
- Egg yolk lecithins
- Egg yolk phosphatides
- Egg yolk phospholipids
- Endolipide component egg lecithin
- Lecithins, egg yolk
- Phospholipids egg
Pharmacology
- Indication
For use as a source of calories for patients requiring parenteral nutrition.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 10% Travamulsion Liq IV Egg phospholipids (1.2 g / 100 mL) + Soybean oil (10 g / 100 mL) Liquid Intravenous Baxter Corporation Clintec Nutrition Division 1995-12-31 2015-08-05 Canada 
20% Travamulsion Liq IV Egg phospholipids (1.2 g / 100 mL) + Soybean oil (20 g / 100 mL) Liquid Intravenous Baxter Corporation Clintec Nutrition Division 1995-12-31 2015-08-05 Canada DAILY-ONE 45 FILM TABLET Egg phospholipids (23 mg) + Ascorbic acid (90 mg) + Beta carotene (2000 IU) + Biotin (0.06 mg) + Calcium phosphate, tribasic (100 mg) + Calcium phosphate, tribasic (50 mg) + Choline bitartrate (3.9 mg) + Chromium nicotinate (0.13 mg) + Cupric sulfate (2 mg) + Cyanocobalamin (0.015 mg) + Ferrous fumarate (18 mg) + Folic acid (0.4 mg) + Inositol (3.9 mg) + Magnesium oxide (40 mg) + Manganese sulfate (3.5 mg) + Niacin (20 mg) + Pantothenic acid (20 mg) + Potassium Iodide (0.15 mg) + Potassium citrate (18 mg) + Pyridoxine hydrochloride (12 mg) + Riboflavin (10.2 mg) + Sodium selenite (0.07 mg) + Sodium molybdate (0.05 mg) + Thiamine hydrochloride (9 mg) + Vitamin A acetate (8000 IU) + Vitamin D (400 IU) + Vitamin E (60 IU) + Zinc gluconate (15 mg) Tablet, film coated FERROSAN SAĞLIK ÜRÜN VE HİZMETLERİ A.Ş. 2020-08-14 Not applicable Turkey 
INTRALIPID 20% Egg phospholipids (1.2 %) + Glycerin (2.25 %) + Soybean oil (20 %) Injection Intravenous FRESENIUS KABI MALAYSIA SDN. BHD 2020-09-08 Not applicable Malaysia 
KABIVEN EMULSION FOR INFUSION Egg phospholipids (2.3 g/1000ml) + Alanine (4.7 g/1000ml) + Arginine (3.3 g/1000ml) + Aspartic acid (0.99 g/1000ml) + Calcium chloride dihydrate (0.29 g/1000ml) + D-glucose monohydrate (107 g/1000ml) + Glutamic acid (1.6 g/1000ml) + Glycerin (4.3 g/1000ml) + Glycine (2.3 g/1000ml) + Histidine (2 g/1000ml) + Isoleucine (1.6 g/1000ml) + Leucine (2.3 g/1000ml) + Lysine hydrochloride (3.3 g/1000ml) + Magnesium sulfate heptahydrate (0.96 g/1000ml) + Methionine (1.6 g/1000ml) + Phenylalanine (2.3 g/1000ml) + Potassium chloride (1.7 g/1000ml) + Proline (2 g/1000ml) + Serine (1.3 g/1000ml) + Sodium acetate trihydrate (2.4 g/1000ml) + Sodium glycerophosphate (1.5 g/1000ml) + Soybean oil (39 g/1000ml) + Threonine (1.6 g/1000ml) + Tryptophan (0.56 g/1000ml) + Tyrosine (0.07 g/1000ml) + Valine (2.1 g/1000ml) Injection Intravenous FRESENIUS KABI (SINGAPORE) PTE LTD 2001-04-09 Not applicable Singapore LIPOFUNDIN MCT/LCT INFUSION 20% Egg phospholipids (12 g/1000ml) + Glycerin (25 g/1000ml) + Medium-chain triglycerides (100 g/1000ml) + Soybean oil (100 g/1000ml) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 1991-08-04 Not applicable Singapore LIPOFUNDIN N EMULSION FOR INFUSION 20 % Egg phospholipids (12 g/1000ml) + Glycerin (25 g/1000ml) + Soybean oil (200 g/1000ml) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 2001-09-21 Not applicable Singapore Liposyn II Egg phospholipids (1.2 g/100mL) + Safflower oil (10 g/100mL) + Soybean oil (10 g/100mL) Injection, emulsion Intravenous Hospira, Inc. 1984-08-27 2011-02-01 US 
Liposyn II Egg phospholipids (1.2 g/100mL) + Safflower oil (5 g/100mL) + Soybean oil (5 g/100mL) Injection, emulsion Intravenous Hospira, Inc. 1984-08-27 2011-02-01 US Liposyn II 10% Egg phospholipids (0.9 %) + Safflower oil (5 %) + Soybean oil (5 %) Emulsion Intravenous Hospira Healthcare Ulc 1987-12-31 2014-08-01 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image OMEGAVEN EMULSIYON Egg phospholipids (1.2 g) + DL-alpha-Tocopherol (0.0223 g) + Doconexent (2.265 g) + Glycerin (2.5 g) + Icosapent (2.035 g) Injection, emulsion Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 2020-08-14 Not applicable Turkey Puralor Egg phospholipids (42.5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphocholine (5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphoethanolamine (2.5 mg/1) + Acetylcysteine amide (5 mg/1) + Ascorbic acid (25 mg/1) + Cholecalciferol (100 [iU]/1) + Citric acid (1.6 mg/1) + Cobamamide (2 mg/1) + Folic acid (42.5 mg/1) + Gastric intrinsic factor (2.5 mg/1) + Magnesium L-threonate (2.5 mg/1) + Leucovorin (3 mg/1) + Levomefolic acid (0.4 mg/1) + Magnesium glycinate (1 mg/1) + Niacin (0.5 mg/1) + Pantethine (2.5 mg/1) + Papain (20 mg/1) + Riboflavin (0.5 mg/1) + Sodium citrate (0.8 mg/1) + Thiamine chloride (0.5 mg/1) Tablet, chewable Oral Centurion Labs 2014-01-01 2017-09-20 US
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1Z74184RGV
- CAS number
- 93685-90-6
References
- General References
- TITCK Product Information: OMEGAVEN (DL-alpha-tocopherol, doconexent, egg phospholipids, glycerin, and icosapent) injection [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Hippel Lindau Disease / Renal Cancer 1 Not Available Terminated Prevention Hypertriglyceridemias 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Liquid Intravenous Tablet, film coated Injection Intravenous Injection Intravenous 12 g/1000ml Emulsion Intravenous Injection, emulsion Intravenous Injection Intravenous 12 g/L Capsule Oral Tablet, chewable Oral - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US9717852 No 2017-08-01 2033-04-08 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at July 05, 2018 02:37 / Updated at June 22, 2021 18:16